/CLPT
CLPT Stock - ClearPoint Neuro, Inc.
Healthcare|Medical - DevicesNASDAQ
$14.20+4.03%
+$0.55 (+4.03%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+111.3%upside
Target: $30.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CLPT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$14.06 – $14.34
TARGET (TP)$30.00
STOP LOSS$13.06
RISK/REWARD1:13.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.01
52W High$30.10
52W Low$9.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $31.39M | $23.95M | $20.55M | $16.30M | $12.83M |
| Gross Profit | $19.12M | $13.61M | $13.53M | $11.12M | $9.12M |
| Gross Margin | 60.9% | 56.8% | 65.8% | 68.2% | 71.1% |
| Operating Income | $-19,746,000 | $-22,446,000 | $-16,332,000 | $-13,374,000 | $-6,220,000 |
| Net Income | $-18,914,000 | $-22,089,000 | $-16,435,000 | $-14,410,000 | $-6,782,000 |
| Net Margin | -60.3% | -92.2% | -80.0% | -88.4% | -52.9% |
| EPS | $-0.70 | $-0.90 | $-0.68 | $-0.69 | $-0.43 |
Company Overview
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↓ 24.9% Downside
Now
$8
Low
$11
Average
$14
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 25th 2024 | B. Riley Securities | Resumed | Buy | $10 |
| October 24th 2023 | Stifel | Initiation | Buy | $8 |
| February 16th 2023 | B. Riley Securities | Resumed | Buy | $14 |
Earnings History & Surprises
CLPTBeat Rate
39%
Last 18 quarters
Avg Surprise
-5.5%
EPS vs Estimate
Beats / Misses
7/9
2 met exactly
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q1 24
+13.6%
$-0.19vs$-0.22
Q2 24
+15.8%
$-0.16vs$-0.19
Q3 24
+15.8%
$-0.16vs$-0.19
Q4 24
-5.9%
$-0.18vs$-0.17
Q1 25
-33.3%
$-0.20vs$-0.15
Q2 25
-46.7%
$-0.22vs$-0.15
Q3 25
-5.0%
$-0.21vs$-0.20
Q4 25
-5.0%
$-0.21vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.22 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.15 | $-0.22 | -46.7% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.15 | $-0.20 | -33.3% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.17 | $-0.18 | -5.9% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.19 | $-0.16 | +15.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.19 | $-0.16 | +15.8% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-0.22 | $-0.19 | +13.6% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.25 | $-0.20 | +20.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.18 | $-0.29 | -61.1% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.18 | $-0.23 | -27.8% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-0.22 | $-0.18 | +18.2% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.18 | $-0.18 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.20 | $-0.17 | +15.0% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.19 | $-0.19 | 0.0% | = MET |
Q4 2021 | Nov 9, 2021 | $-0.16 | $-0.18 | -12.5% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.14 | $-0.17 | -21.4% | ✗ MISS |
Latest News
ClearPoint Neuro Narrows FY2025 Sales Guidance from $36.000M-$41.000M to $36.000M-$38.000M vs $37.650M Est
📉 NegativeBenzinga•Nov 6, 2025, 10:02 PM
ClearPoint Neuro shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 6, 2025, 10:01 PM
ClearPoint Neuro Q3 EPS $(0.21) Misses $(0.20) Estimate, Sales $8.861M Miss $9.600M Estimate
📉 NegativeBenzinga•Nov 6, 2025, 09:59 PM
ClearPoint Neuro To Acquire IRRAS Holdings For $5M In Cash, ~1.3M In Common Shares
📈 PositiveBenzinga•Nov 6, 2025, 09:57 PM•Also: ,
ClearPoint Neuro shares are trading higher after the company announced results from a Phase I-II clinical study evaluating the ClearPoint Prism Neuro Laser Therapy System's safety, feasibility and efficacy.
📈 PositiveBenzinga•Oct 8, 2025, 03:13 PM
ClearPoint Neuro Reports Phase I-II Results For Prism Laser System In Glioblastoma Study; Improved Survival Compared To Matched Open Surgery Controls; Safe, Feasible, And Reproducible Workflow; Median Ablation Time: 6.5 Minutes
📈 PositiveBenzinga•Oct 7, 2025, 08:17 PM
ClearPoint Neuro Secures Regulatory Approvals In Canada, Hong Kong, And Taiwan, Expanding Clinical Access To 34 Countries
📈 PositiveBenzinga•Oct 6, 2025, 08:13 PM
ClearPoint Neuro shares are trading higher after the company announced the development and demonstration of its Robotic Neuro-Navigation System.
📈 PositiveBenzinga•Oct 2, 2025, 04:39 PM
ClearPoint Neuro Unveils Robotic Neuro-Navigation System To Advance Cell And Gene Therapy Procedures
📈 PositiveBenzinga•Oct 1, 2025, 08:10 PM
ClearPoint Neuro Announces The Development And Demonstration Of Its Robotic Neuro-Navigation System
📈 PositiveBenzinga•Oct 1, 2025, 08:09 PM
ClearPoint Neuro Secures FDA Clearance For 1.5T MRI Use, Expanding Reach For Prism Neuro Laser System
📈 PositiveBenzinga•Sep 4, 2025, 08:10 PM
Frequently Asked Questions about CLPT
What is CLPT's current stock price?
ClearPoint Neuro, Inc. (CLPT) is currently trading at $14.20 per share. The stock has moved +4.03% today.
What is the analyst price target for CLPT?
The average analyst price target for CLPT is $30.00, based on 1 analyst.
What sector is ClearPoint Neuro, Inc. in?
ClearPoint Neuro, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is CLPT's market cap?
ClearPoint Neuro, Inc. has a market capitalization of $0.40 billion, making it a small-cap company.
Does CLPT pay dividends?
No, ClearPoint Neuro, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAKBA
Akebia Therapeutics, Inc.
$1.66
Mkt Cap: $0.4B
AVNS
Avanos Medical, Inc.
$11.67
Mkt Cap: $0.5B
CMPS
COMPASS Pathways plc
$6.37
Mkt Cap: $0.6B
CTKB
Cytek Biosciences, Inc.
$4.95
Mkt Cap: $0.6B
LAB
Standard BioTools Inc.
$1.63
Mkt Cap: $0.6B
OFIX
Orthofix Medical Inc.
$15.46
Mkt Cap: $0.6B
SIBN
SI-BONE, Inc.
$20.38
Mkt Cap: $0.9B
SNDL
SNDL Inc.
$1.92
Mkt Cap: $0.5B
SRDX
Surmodics, Inc.
$42.98
Mkt Cap: $0.6B
VREX
Varex Imaging Corporation
$12.29
Mkt Cap: $0.5B
Explore stocks similar to CLPT for comparison